ALK and non-small cell lung carcinoma: Updated results from the Phase 3 CROWN trial, which evaluated lorlatinib versus crizotinib in people with previously untreated (ALK)-positive advanced NSCLC, reported that after a median follow-up of three years lorlatinib continues to demonstrate meaningful improvement in PFS compared to crizotinib (HR, 0.27; 95% CI, 0.18–0.39), corresponding to a 73% reduction in the rate of progression or death. Moreover, lorlatinib treatment resulted in a 92% reduction in the rate of intracranial progression (HR, 0.08; 95% CI, 0.04–0.17).